Mark James Litton - Jan 27, 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Executive Officer, Director
Signature
/s/ Glenna Mileson, Attorney-in-fact on behalf of Mark Litton
Stock symbol
ATHA
Transactions as of
Jan 27, 2022
Transactions value $
$11,071
Form type
4
Date filed
1/31/2022, 04:06 PM
Previous filing
Aug 19, 2021
Next filing
Jun 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Award $11.1K +885 +0.77% $12.51 116K Nov 18, 2021 Direct F1, F2, F3
holding ATHA Common Stock 6.56K Jan 27, 2022 By Irrevocable Trust of OSL F4
holding ATHA Common Stock 6.56K Jan 27, 2022 By Irrevocable Trust of SWL F5
holding ATHA Common Stock 6.56K Jan 27, 2022 By Irrevocable Trust of WGL F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +400K $0.00 400K Jan 27, 2022 Common Stock 400K $9.91 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).
F2 The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.
F3 In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.
F4 Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children.
F5 Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children.
F6 Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children.
F7 One-forty eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.